 |
 |
|
 |
Every good idea brings a real opportunity
At Grifols, taking on responsibility means showing full commitment to therapeutic advances and the progress of related new scientific knowledge.
eALTA is a European research initiative funded by Bayer HealthCare Biological Products in 2004 and continued by Talecris Biotherapeutics GmbH. Grifols now is proud to continue the commitment to the Alpha-1 community.
Through eALTA, we promote the realisations of innovative ideas and visions in the field of Alpha-1-Antitrypsin Deficiency (AATD). Our aim is to give novel ideas a real chance. eALTA offers the award winners scientific and financial freedom to pursue clinical and scientific research in AATD and AATD associated diseases - and consequently help to shape the future of AATD therapy.
Grifols funds two research projects each year. With an annual prize fund of EUR 50,000 per fellowship, eALTA is one of the most significant awards in the field of respiratory research.
|
Letters of Intent due March 1st 
|
|
||
